Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046729 · ClinicalTrials.gov registry record · Phase 2
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 352
- Enrollment target
- 20
- Study locations
NCT06046729: Active Phase 2 study of Hidradenitis Suppurativa, sponsored by Eli Lilly and Company.
NCT06046729 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 352 participants, below the 591-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06046729, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 352 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eltrekibart
Study Locations (20)
Florida
- Direct Helpers Research Center - Hialeah
- University of Miami - Miami
- Skin Research of South Florida - Miami
- ForCare Clinical Research - Tampa
- Alliance Clinical Research of Tampa - Tampa
- Olympian Clinical Research - Tampa
California
- First OC Dermatology Research Inc - Fountain Valley
- Center For Dermatology Clinical Research, Inc. - Fremont
- Dermatology Research Associates - Los Angeles
- Dermatology Institute and Skin Care Center - Santa Monica
Arizona
- Medical Dermatology Specialists - Phoenix
- Saguaro Dermatology Associates, LLC - Probity - PPDS - Phoenix
Arkansas
- Arkansas Research Trials, LLC - North Little Rock
- Northwest Arkansas Clinical Trials Center - Rogers
Kentucky
- Equity Medical - Bowling Green - Bowling Green
- Derm Research LLC - Louisville
Connecticut
- University of Connecticut - Farmington
Georgia
- Advanced Medical Research, PC - Sandy Springs
Illinois
- NorthShore Medical Group Dermatology - Skokie - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What the registry record for NCT06046729 still lists
NCT06046729 is an interventional study that assigns participants to a tested intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, below the 591-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06046729 names 20 study sites across 9 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06046729 about?
NCT06046729 is a clinical study titled "A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa". This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
What is the current status of trial NCT06046729?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 352 participants. The study started on 2023-10-23. Estimated completion is 2026-08.
What conditions does trial NCT06046729 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06046729?
The interventions under investigation include: Placebo (DRUG), Eltrekibart (DRUG).
Who is sponsoring clinical trial NCT06046729?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046729 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06046729's enrollment target sits among peer trials
352 17th of 52 higher than 36 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05811936 · 352 participants · NA
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI